Background: Whether continuous proton pump inhibitor (PPI) therapy is superior to on-demand therapy for symptom control of Barrett's esophagus patients is unclear. The study aimed to compare the efficacies of the symptom control and the frequency of co-existent erosive esophagitis in patients with Barrett's esophagus by either continuous or on-demand PPI therapy.
Methods: We randomly assigned (1:1) consecutive adult patients with symptomatic Barrett's esophagus to receive on-demand or continuous esomeprazole (40 mg q.d.) therapy for 40 weeks following an initial treatment with esomeprazole 40 mg daily for 8 weeks. A follow-up endoscopy was conducted at week 48. The primary outcome was total number of symptomatic days. The secondary outcome was the frequency of co-existent erosive esophagitis at week 48.
Results: From February 2010 to December 2022, we randomly assigned 235 eligible patients to receive either on-demand (n = 119) or continuous (n = 116) esomeprazole therapy. The on-demand and continuous groups did not signicantly differ in symptom scores at each follow-up time point. Two treatment groups had a comparable total number of symptom days (27.7 ± 41.5 vs 24.3 ± 47.7; P = 0.570) but the on-demand group took fewer esomeprazole tablets than the continuous group (230.6 ± 96.5 vs 330.0 ± 15.6; P < 0.001). At week 48, the on-demand and continuous groups had comparable frequencies of erosive esophagitis (10.6% vs 6.7%).
Conclusion: On-demand PPI therapy reduces the total amount of PPI used while achieving similar symptom relief compared to continuous PPI therapy in patients with Barrett's esophagus.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jfma.2025.03.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of continuous versus on-demand proton pump inhibitor therapy in symptom control of patients with Barrett's esophagus.
J Formos Med Assoc
March 2025
Division of Gastroenterology and Hepatology, Department of Internal Medicine, An Nan Hospital, China Medical University, Tainan, Taiwan. Electronic address:
Background: Whether continuous proton pump inhibitor (PPI) therapy is superior to on-demand therapy for symptom control of Barrett's esophagus patients is unclear. The study aimed to compare the efficacies of the symptom control and the frequency of co-existent erosive esophagitis in patients with Barrett's esophagus by either continuous or on-demand PPI therapy.
Methods: We randomly assigned (1:1) consecutive adult patients with symptomatic Barrett's esophagus to receive on-demand or continuous esomeprazole (40 mg q.
Aims: This study aims to investigate the correlation between the neutrophil-lymphocyte ratio (NLR) and advancing stages of Barrett's esophagus (BE) to esophageal adenocarcinoma (EAC).
Methods And Results: A retrospective cohort of patients diagnosed with BE and EAC were analyzed. Cases were categorized into four groups according to their histological diagnosis: non-dysplastic BE (NDBE), low-grade dysplasia (LGD), high-grade dysplasia (HGD), and EAC.
High Risk of Persistence and Risk of Dysplasia after Ultrashort Barrett's Diagnosis.
Am J Gastroenterol
March 2025
Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Background: The management of ultrashort (< 1cm) Barrett's esophagus (BE) remains unclear. We aimed to determine the prevalence of ultrashort BE (USBE) at index diagnosis, identify factors associated with persistent BE after USBE diagnosis, and identify risk of dysplasia after initial USBE in a population of United States veterans.
Methods: This was a retrospective cohort study at the Veterans Affairs hospital in Houston, TX of consecutive patients with new BE diagnosis from 11/1990 to 6/2022 with follow-up through 4/2023.
[The role of surgery in preventing esophageal cancer].
Bull Cancer
March 2025
Hôpital Claude-Huriez, université de Lille, CHU de Lille, service de chirurgie digestive et oncologique, 59000 Lille, France; University Lille, CHU de Lille, CNRS, UMR9020-U1277-CANTHER-Cancer, Inserm, 59000 Lille, France.
The prognosis for esophageal cancer remains poor because it is often diagnosed late and patients often have unfavourable backgrounds. This is reflected in standardised 5-year net survival rates of no more than 20%, regardless of gender. Unlike gastric cancer (CDH1 gene mutation), there is currently no genetic predisposition to esophageal cancer that would justify prophylactic esophagectomy.
View Article and Find Full Text PDFArtificial Intelligence Applications in Image-Based Diagnosis of Early Esophageal and Gastric Neoplasms.
Gastroenterology
March 2025
Department of Hospital Pathology, College of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul 06591, South Korea. Electronic address:
Artificial intelligence (AI) holds the potential to transform the management of upper gastrointestinal (GI) conditions, such as Barrett's esophagus, esophageal squamous cell cancer, and early gastric cancer. Advancements in deep learning (DL) and convolutional neural networks offer improved diagnostic accuracy and reduced diagnostic variability across different clinical settings, particularly where human error or fatigue may impair diagnostic precision. DL models have shown the potential to improve early cancer detection and lesion characterization, predict invasion depth, and delineate lesion margins with remarkable accuracy, all contributing to effective treatment planning.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!